Donna Rill

Ms. Rill joined Triumvira as Chief Technology Officer in June 2018. Prior to Triumvira, Ms. Rill, an accomplished expert in cellular therapy manufacturing, was responsible for the design and qualification of cell & gene therapy laboratories using novel technologies, cGMP vector production facilities, core service laboratories, and translational research laboratories. In addition to her construction, project management and regulatory/QA/QC/(c)GxP knowledge, she brings extensive operational and strategic experience in cell and gene therapy, monoclonal antibody production, and protein production. Ms. Rill will oversee all North American operations for Triumvira.

Ms. Rill’s earlier positions include Vice President of Manufacturing for Cell Medica, Chief Development Officer for Opexa Therapeutics, Laboratory Director of Cell and Gene Therapy at Baylor College of Medicine (Head: Prof. Malcolm Brenner); and Lab Manager of the GMP Cell & Gene Therapy Laboratories at St. Jude Children’s Research Hospital.